Cargando…

Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis

BACKGROUND: Current therapeutic options have limited efficacy for patients with advanced gastric or gastroesophageal junction cancer. Immune checkpoint inhibition now has been increasingly used in advanced gastric or gastroesophageal junction cancer therapy. To further understand the efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bi-Cheng, Zhang, Zhan-Jie, Fu, Chen, Wang, Chang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882659/ https://www.ncbi.nlm.nih.gov/pubmed/31764833 http://dx.doi.org/10.1097/MD.0000000000018054

Ejemplares similares

PD-L1/PD-1 check-point in gastric carcinoma with lymphoid stroma case report with immunochemical study
por: Crescenzi, Anna, et al.
Publicado: (2017)

Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
por: Yang, Li, et al.
Publicado: (2020)

Real‐world clinical outcomes of the combination of anti‐PD‐1 antibody, trastuzumab, and chemotherapy for HER2‐positive gastric/gastroesophageal junction cancer
por: Yang, Ju, et al.
Publicado: (2023)

Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
por: Liu, Bo-Wei, et al.
Publicado: (2023)

Efficacy and safety of ERCP in patients with gastroesophageal varices
por: Hong, Junbo, et al.
Publicado: (2020)

Perioperative treatment and biomarker analysis of LP002, an anti‐PD‐L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer
por: Tang, Jia‐lin, et al.
Publicado: (2022)

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis
por: Yuan, Zhen, et al.
Publicado: (2023)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
por: Brar, Gagandeep, et al.
Publicado: (2019)

A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
por: Voutsadakis, Ioannis A
Publicado: (2020)

Identification of biomarkers associated with diagnosis and prognosis of gastroesophageal junction adenocarcinoma–a study based on integrated bioinformatics analysis in GEO and TCGA database
por: Song, Danlei, et al.
Publicado: (2020)

Comparisons of Clinical Outcomes and Prognoses in Patients With Gastroesophageal Junction Adenocarcinoma, by Transthoracic and Transabdominal Hiatal Approaches: A Teaching Hospital Retrospective Cohort Study
por: Zhou, Jinzhe, et al.
Publicado: (2015)

Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer
por: Guo, Qinghong, et al.
Publicado: (2017)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Reflux episodes and esophageal impedance levels in patients with typical and atypical symptoms of gastroesophageal reflux disease
por: Ye, Bi Xing, et al.
Publicado: (2017)

Seattle protocol vs narrow band imaging guided biopsy in screening of Barrett's esophagus in gastroesophageal reflux disease patients
por: Elsheaita, Ahmed, et al.
Publicado: (2020)

Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis
por: Oh, SuA, et al.
Publicado: (2021)

Peroral endoscopic cardial constriction in gastroesophageal reflux disease
por: Hu, Hai-Qing, et al.
Publicado: (2018)

The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients
por: Yan, Long, et al.
Publicado: (2019)

Laparoscopic revision surgery for gastroesophageal reflux disease
por: Celasin, Haydar, et al.
Publicado: (2017)

A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer
por: Wu, Fang-Lan, et al.
Publicado: (2015)

Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis
por: Zheng, Zheng, et al.
Publicado: (2020)

Effectiveness and safety of reduced-port laparoscopic surgery vs conventional multi-port laparoscopic surgery in the treatment of gastric diseases: A meta-analysis
por: Yang, Xu, et al.
Publicado: (2021)

High Incidence of Malaria Along the Sino–Burmese Border Is Associated With Polymorphisms of CR1, IL-1A, IL-4R, IL-4, NOS, and TNF, But Not With G6PD Deficiency
por: Ren, Na, et al.
Publicado: (2015)

Association between gastroesophageal reflux disease and vocal fold polyps
por: Zou, Yazhu, et al.
Publicado: (2021)

Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis
por: Lv, Yalei, et al.
Publicado: (2021)

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
por: Fashoyin‐Aje, Lola, et al.
Publicado: (2018)

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
por: Lu, Zhihao, et al.
Publicado: (2022)

Efficacy and safety of PD‑1/PD‑L1 inhibitors combined with chemotherapy in patients with advanced gastric or gastro‑esophageal junction cancer: A systematic review and meta‑analysis
por: Su, Shiqing
Publicado: (2023)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
por: Chen, Meng, et al.
Publicado: (2022)

Is Atrial Fibrillation a Risk Factor for Gastroesophageal Reflux Disease Occurrence?
por: Hwang, Jae Jin, et al.
Publicado: (2015)

Association between gastroesophageal reflux disease and depression disorder: A protocol for systematic review and meta-analysis
por: Liu, Yu, et al.
Publicado: (2020)

Efficacy of acid suppression therapy in gastroesophageal reflux disease-related chronic laryngitis
por: Yang, Yue, et al.
Publicado: (2016)

Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma
por: Tsai, Wei-Lun, et al.
Publicado: (2020)

The prevalence of coronary atherosclerosis in patients with refractory gastroesophageal reflux disease ready for antireflux surgery
por: Zhang, Xiumei, et al.
Publicado: (2022)

PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma
por: Hußtegge, Marlon, et al.
Publicado: (2021)

The prognostic values of estrogen receptor alpha and beta in patients with gastroesophageal cancer: A meta-analysis
por: Zhang, Dongyun, et al.
Publicado: (2019)

Salivary peptest for laryngopharyngeal reflux and gastroesophageal reflux disease: A systemic review and meta-analysis
por: Guo, Zihao, et al.
Publicado: (2021)

Laparoscopic fundoplication in treating refractory gastroesophageal reflux-related chronic cough: A meta-analysis
por: Liu, Jiannan, et al.
Publicado: (2023)

Clinical significance of ubiquilin 1 in gastric cancer
por: Bao, Jingjing, et al.
Publicado: (2018)

The safety of vedolizumab in a patient with Crohn’s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report
por: Sugiyama, Yuya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j6o7dboa0d80bi2dnemdkpld20